Ozempic Could Change Births in America
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
More babies could be born because of Ozempic as it can improve fertility and has led to surprise pregnancies, experts have told Newsweek.
There have been multiple reports of an "Ozempic babies" phenomenon after women reported becoming pregnant on the drug, even while on birth control in some cases.
Last month, the United Kingdom's Medicines and Healthcare products Regulatory Agency, an executive agency of the Department of Health and Social Care, urged women on Ozempic and other similar weight loss drugs to make sure they are on effective birth control if they do not want to conceive.
Professor Alexander Miras, a clinical professor of medicine who has led studies on how weight loss interventions influence live birth rates in women with polycystic ovary syndrome (PCOS), told Newsweek that this is happening because women with obesity often have no periods and do not routinely use contraception.
Photo-illustration by Newsweek/GettyCanva
"Medications for obesity cause significant weight loss and this can rapidly improve fertility, thus the unwanted pregnancies," he said.
Similarly, reproductive endocrinologist Dr. Patricia Jimenez, from WashU Medicine, told Newsweek: "For people with irregular menstrual cycles, weight loss has been shown to increase ovulation and therefore pregnancy."
"Weight loss also can improve semen parameters," she added.
However, Jimenez stressed that these drugs "are not fertility medications, and for people struggling with infertility, the best option is to talk with a specialist about fertility treatment."
Meanwhile Karin Hammarberg, a senior research fellow at Monash University who has authored several pieces on "Ozempic babies," said that unwanted pregnancies from weight loss drugs could be a cause for concern.
"They will cause some unexpected and unplanned pregnancies, which is concerning since we don't know how this drug might affect the growing fetus," she told Newsweek.
While a lot is still unknown about Ozempic, its ability to affect fertility may have an impact on the number of births in America, which is, along with most other countries, struggling with declining birth rates.
Could Ozempic Lead to an Increase in Birth Rates?
"We may indeed observe an increase in birth rates because a previously untreated population of women with infertility will now have more access to effective pharmacotherapy for obesity that can rapidly improve their fertility," Miras said.
While Hammarberg agrees that weight loss drugs could add a number of births to the total, she does not believe it "will make any difference to birth rates at a population level."
Jimenez said "we need more data to understand whether these medications will have a significant impact on birth rates" as "there is no evidence that weight loss increases live birth rates in people with regular ovulatory cycles or with fertility treatments."
America's fertility rates are projected to average 1.6 births per woman over the next three decades, according to the Congressional Budget Office's latest forecast released this year.
This number is well below the replacement level of 2.1 births per woman required to maintain a stable population without immigration.
With financial struggles and worries often cited as reasons for people having fewer children, solutions often focus on calling for policies that include making child care, health care, housing and education more accessible.
Others have focused on cultural impacts. For example, Norway is a global leader in parental leave and child care policies, but is still facing a birth rate crisis. Its Birth Rate Committee has pointed largely to cultural changes, including the fact that fewer people are having their first child before the age of 30 because lower rates of couples in their 20s are staying together.
Dr. Jonathan Sher, founding partner of Scotland's Coalition for Healthier Pregnancies, Better Lives and the former deputy director of the Queen's Nursing Institute Scotland, is one of several who have urged countries to look at fertility and pregnancies as a way of tackling birth rates.
He previously wrote that remedies linked to finances are "built on the assumption that people of childbearing potential are increasingly choosing not to become parents."
Sher said that focusing on achieving healthier fertility and pregnancies could save multiple "unhappy endings" which includes miscarriages, stillbirths, therapeutic terminations, very premature deliveries, harm to the mother's health and/or her future reproductive life, as well as babies born with life-limiting birth defects.
"These are pregnancies intended to be full term and produce healthy babies who will grow up to become net assets to their economies and societies," Sher said.
Although saving all of these pregnancies would be impossible, "many of these unwelcome outcomes could, and should, have been prevented through robust, universal, effective policies and practices under the umbrella of preconception and interconception health, education and care," he said.
How Does Ozempic Work?
Ozempic is an injectable prescription drug that was developed to manage blood sugar levels in patients with Type 2 diabetes. It has surged in popularity because of how it assists weight loss.
It is based on a naturally occurring human hormone called glucagon-like peptide 1 (GLP-1), which plays an important role in regulating appetite and blood sugar levels. Its active ingredient is a molecule called semaglutide, which mimics the structure of this GLP-1 hormone and activates its receptors.
In doing so, semaglutide induces feelings of fullness while delaying the emptying of the stomach, making users feel less hungry and therefore less likely to overeat.
Jamie Winn, of the online pharmacy Universal Drugstore, previously told Newsweek that "Ozempic may interfere with the absorption of oral contraceptives, which can reduce their effectiveness and lead to an unwanted pregnancy."
"If you are taking Ozempic and an oral contraceptive, it is recommended that you also use a barrier method of birth control such as a condom," Winn added. "Another option is to switch to a long-acting reversible contraceptive such as an IUD."
But, like Jimenez, Winn said: "While Ozempic may increase fertility, caution should be taken if you get pregnant while on this medication. There is not enough information on the use of Ozempic by pregnant women, and there were adverse outcomes in animal studies. Pregnant rats that were given Ozempic had an increased rate of fetal death and birth defects.
"Because it can take up to six weeks for Ozempic to be cleared from your body, it is recommended that you stop Ozempic at least two months before you plan on getting pregnant," Winn said. "If you become pregnant or think you are pregnant while on Ozempic, stop taking the medication and call your health care provider immediately."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
7 minutes ago
- Newsweek
Tea Recalled Nationwide as FDA Sets Risk Level
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A nationwide and cross-border recall of a popular relaxation tea, initiated after an ingredient mixup, has been designated by food inspectors as the second-highest risk level. Herbalife International of America, which is based in Los Angeles, issued a voluntary recall of its Relaxation Tea on July 21. The recall affects 5,888 products sold online across the United States as well as in Mexico and Ecuador. On August 6, the U.S. Food and Drug Administration (FDA) classified the recall as a Class II risk—a designation indicating products may cause temporary or medically reversible adverse health consequences. No press release was issued and the FDA's classification alert did not state which ingredients had been mixed up. Newsweek has contacted Herbalife via email outside of regular office hours on Thursday. Why It Matters The FDA's decision to classify the recall as a Class II risk signals a significant, though not life-threatening, potential for harm. Class II recalls address situations where the use of a product could cause temporary or medically reversible adverse effects, or the probability of serious consequences is remote. Stock image shows a woman smelling tea at sunset. Stock image shows a woman smelling tea at sunset. Getty Images What To Know The FDA said the recall stemmed from the use of an "incorrect ingredient received from supplier and used in manufacturing finished product Relaxation Tea." The items' lot code, which is often found near the product's bar code, is: D925507J02. The expiration date is 04/11/2027, the FDA alert said. Herbalife advised customers not to use the affected Relaxation Tea products. FDA inspectors assign recalls one of three classifications—Class I, Class II, or Class III—to indicate the degree of hazard to people's health. The classifications are defined by the agency as: Class I - a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death. Class II - a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. Class III - a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences. What Happens Next Consumers who purchased Herbalife Relaxation Tea are urged to check their packaging and discontinue use of any recalled units. Customers with affected products or safety concerns are advised to contact Herbalife's customer service or review the FDA's recall posting for detailed guidance.
Vogue
7 minutes ago
- Vogue
You Can Get Ozempic Online Without a Prescription. Is it Safe?
Whatever your stance is on using the diabetes drug Ozempic to assist with weight loss, there's no denying that its popularity is at an all-time high. In fact, a survey by independent information organization KFF found that one in eight adults in the US has taken a GLP-1 at least once in their life. Makes sense that we had a GLP-1 shortage last year—intertwining with a new means of getting the drug for those who previously may not have been prescribed: KFF also reported that 11% of people are getting their GLP-1 drug from an online provider or website. Experts say that lower costs and easy access seem to be the driving factors. Holly Lofton, MD, director of the medical weight management program at NYU Langone Health, explains that GLP-1s and other similar medications can cost well over $1,000 per month without insurance. Dr. Lofton adds that many prescribers may not feel comfortable prescribing these medications ('They have not been properly trained or don't understand the complexity of overweight and obesity as chronic medical conditions,' she says), making it difficult for patients to get the drug from their primary care physicians. These online platforms make it convenient for consumers looking to avoid having to go back and forth with their insurance and doctors, with a catch: They can be unregulated. 'This convergence of unmet demand and commercial supply has driven individuals toward alternative channels,' says Peter Goulden, MD, FRCP, division chief of the division of endocrinology, diabetes, and bone diseases at Mount Sinai. 'Often without full appreciation of the clinical risks involved.' The Risks Dr. Goulden says unregulated sources and the absence of clinical screenings of these drugs may lead to incorrect dosages, counterfeit products, or ineffective or contaminated products that can cause serious adverse effects such as dehydration, hypoglycaemia, and infection. You also risk not having access to regular monitoring with a licensed professional. Without a doctor or medical professional coaching you through long-term treatment, he says you risk possible negative interactions with medications you're already taking or worsening renal function, gallbladder disease, or pancreatitis. 'Circumventing the standard medical framework in favor of online acquisition undermines the safeguards designed to ensure appropriate, evidence-based use of these potent agents,' he says. The Compound Issue Compounded options also continue to grow in popularity online—causing great concern. Compounded medication, as Dr. Goulden explains it, is a drug that has been custom-made by a pharmacy onsite. It typically involves combining, mixing, or altering ingredients to meet the specific needs of a patient. It is only permitted when there is a genuine shortage of a commercial drug or when a patient has a specific need for it (e.g., an allergy to a preservative in the original medication) that the standard drug cannot provide. When it comes to compounded Ozempic and other semaglutides, Dr. Goulden adds that they are not identical to their FDA-approved counterparts and are not subjected to the same rigorous testing or quality control. The FDA recently reported its concerns on fraudulent compounded GLP-1s in the market, where some don't even contain semaglutide at all.
New York Times
an hour ago
- New York Times
How Ozempic's Maker Lost Its Shine After Creating a Wonder Drug
For years, there was no stopping Novo Nordisk, the Danish drugmaker behind Ozempic. Its diabetes drug became a cultural phenomenon for its ability to induce drastic weight loss while also reducing the risk of heart attacks and other serious diseases in people with obesity. Its potential to transform the health care industry made it a darling of the stock market, surging to become the most valuable company in Europe. Then, suddenly, its fortunes took a turn. Novo Nordisk's share price has plummeted more than 50 percent this year, pushing it out of the top ten list of Europe's most valuable companies. The company bewildered analysts in May when it abruptly said it would replace its chief executive, and it has seemed unable to keep ahead of competition from the American drugmaker Eli Lilly and the prevalence of cheap copycat versions. 'The market's got no patience for Novo,' said Gareth Powell, the head of health care at Polar Capital, a fund manager. 'Sentiment is absolutely dire.' It has been a stunning reversal for the company behind a drug that physicians once called a game changer. On Wednesday, Novo Nordisk reported $24 billion in global sales in the first six months of the year, but reiterated that it expects growth to slow in the rest of the year, which it first flagged in a profit warning last week. The company's stock tumbled more, as analysts and investors expressed doubts about whether there was much the company could do to revive its prospects in the short term. Novo Nordisk is 'a company with incredible history and capabilities, and they've got a pipeline,' Mr. Powell said. 'It's just the market's putting zero value on it. Source: FactSet By The New York Times Source: IQVIA By The New York Times Want all of The Times? Subscribe.
